Vorasidenib

4 trials 2 recruiting LOncology Orphan designation

Filter these 4 trials by condition, phase, country and more.

Open in Search →

4 Registered trials

2 Recruiting

2 Completed trials

3 Sponsors

9 Countries

Phase III

Phase II

Phase I/II

Phase III: 2 Phase II: 1 Phase I/II: 1

Indications tested

Glioma 2 Astrocytoma malignant 1

Sponsors using this IMP

Institut De Recherches Internationales Servier IRIS 2 Europese Organisatie Voor Onderzoek En Behandeling Van Kanker Organisation Europeenne Pour La Recherche Et Le Traitement Du Cancer European Organi 1 Oslo University Hospital HF 1

All trials

4 total

Vorasidenib for the treatment of IDH-mutant astrocytoma after standard chemoradiotherapy Recruiting

2024-519404-27-00 Phase III 8 countries Europese Organisatie Voor Onderzoek En Behandeling Van Kanker Organisation Europ…
Precision cancer medicine in hard-to-treat rare cancers - repurposing drugs in earlier lines of treatment - MATRIX-RARE. Recruiting

2024-513779-42-02 Phase II 1 country Oslo University Hospital HF
A Phase 1b/2, multicenter study of vorasidenib in combination with temozolomide (TMZ) in participants with IDH1- or IDH2-mutant glioma Ended

2024-513738-39-00 Phase I/II 6 countries Institut De Recherches Internationales Servier IRIS
Study of AG-881 in Subjects With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation Ended

2024-512961-15-00 Phase III 5 countries Institut De Recherches Internationales Servier IRIS

Showing 1–4 of 4 trials

← All drugs A–Z